KR960700739A - Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) - Google Patents

Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) Download PDF

Info

Publication number
KR960700739A
KR960700739A KR1019950703753A KR19950703753A KR960700739A KR 960700739 A KR960700739 A KR 960700739A KR 1019950703753 A KR1019950703753 A KR 1019950703753A KR 19950703753 A KR19950703753 A KR 19950703753A KR 960700739 A KR960700739 A KR 960700739A
Authority
KR
South Korea
Prior art keywords
amino acid
group
composition
terminus
hla
Prior art date
Application number
KR1019950703753A
Other languages
English (en)
Inventor
하워드 엠. 그레이
알레산드로 셋트
존 시드니
더블유. 마틴 캐스트
Original Assignee
카린 이스텀
사이텔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카린 이스텀, 사이텔 코포레이션 filed Critical 카린 이스텀
Publication of KR960700739A publication Critical patent/KR960700739A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 특히 HLA-A2. 1 대립인자에 의해 암호화된 당단백질을 결합하고 A2. 1 대립인자에 의해 제한된 T세포에서 T세포 활성을 유도할 수 있는 면역원성 펩티드 및 면역원성 펩티드 조성물을 선택하는 수단 및 방법을 제공한다. 상기 펩티드는 목적하는 항원에 대한 면역 반응을 유도하는데 유용하다.

Description

HLA-A2. 1 결합 펩티드 및 그의 용도(HLA-A2. 1 BINDING PEPTIDES AND THEIR USED)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HLA-A 정제 도식의 흐름도이다.
제2도는 9량체 펩티드에 대한 "그룹화된 비율"알고리듬에 대해 플롯팅한 상대 결합의 로그값에 대한 산포도를 나타낸다.
제3도는 9량체 펩티드에 대한 평균 "결합 로그"알고리듬 범위에 대해 플롯팅한 상대 결합의 로그값에 대한 산포도를 나타낸다.
제4도 및 5도는 "그룹화된 비율" 및 "결합 로그"알고리듬에 의해 범위를 정한, 2 및 10번 위치에서 바람직한 잔기를 함유하는 일련이 10량제 펩티드에 대한 산포도를 나타낸다.

Claims (23)

  1. 9개 잔기; I, V, A 및 T로 구성되는 그룹중에서 선택된 N-말단의 두번째 위치에서 보존된 첫번째 잔기; 및 V, L, I, A 및 M으로 구성되는 그룹중에서 선택된 C-말단 위치에서 보존된 두번째 잔기를 갖고, HLA-A2.1 결합 모티프를 갖는 면역원성 펩티드를 포함하는 조성물.
  2. 9개 잔기; L, M, I, V, A 및 T로 구성되는 그룹중에서 선택된 N-말단의 두번째 위치에서 보존된 첫번째 잔기; 및 A 및 M으로 구성되는 그룹중에서 선택된 C-말단 위치에서 보존된 두번재 잔기를 갖고 HLA-A2.1 결합 모티프를 갖는 면역원성 펩티드를 포함하는 조성물.
  3. 제1항에 있어서, 1번 위치의 아미노산이 D 및 P로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  4. 제2항에 있어서, 1번 위치의 아미노산이 D 및 P로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물.
  5. 제1항에 있어서, N-말단의 3번 위치의 아미노산이 D, E, R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  6. 제2항에 있어서, N-말단의 3번 위치의 아미노산이 D, E, R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  7. 제1항에 있어서, N-말단의 6번 위치의 아미노산이 R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  8. 제2항에 있어서, N-말단의 6번 위치의 아미노산이 R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  9. 제1항에 있어서, N-말단의 7번 위치의 아미노산이 R, K, H, D 및 E로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  10. 제2항에 있어서, N-말단의 7번의 위치의 아미노산이 R, K, H, D 및 E로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  11. 약 10개의 전지; L M I V A 및 T로 구성되는 그룹중에서 선택된 N-말단의 두번째 위치에서 보존된 첫번째 잔기; 및 V I L A 및 M으로 구성되는 그룹중에서 선택된 C-말단 위치에서 보존된 두번째 잔기를 갖고; 상기 보존된 첫번째 및 두번째 잔기가 7개 잔기에 의해 분리되는, HLA-A2.1 결합 모티프를 갖는 면역 원성 펩티드를 포함하는 조성물
  12. 제11항에 있어서, 1번 위치의 아미노산이 D, E 및 P로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  13. 제11항에 있어서, N-말단의 3번 위치의 아미노산이 D 및 E로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  14. 제11항에 있어서, N-말단의 4번 위치의 아미노산이 A, K, R 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  15. 제11항에 있어서, N-말단의 5번 위치의 아미노산이 P가 아닌 조성물
  16. 제11항에 있어서, N-말단의 7번 위치의 아미노산이 R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  17. 제11항에 있어서, N-말단의 8번 위치의 아미노산이 D, E, R, K 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  18. 제11항에 있어서 N-말단의 9번 위치의 아미노산이 R, K, 및 H로 구성되는 그룹중에서 선택된 아미노산이 아닌 조성물
  19. HLA-A2.1 분자를 결합하고 포유동물의 면역반응을 유도할 수 있는 치료 효과량의 펩티드 및 약학적으로 허용가능한 담체를 포함하는 약학 조성물
  20. 제19항에 있어서, 상기 펩티드가 일반식 TLGIVCPI를 갖는 약할 조성물
  21. 제19항에 있어서, 일반식 TMLDLQPETT를 갖는 펩티드를 또한 포함하는 약학 조성물
  22. 제19항에 있어서, T보조자 펩티드를 또한 포함하는 약학 조성물
  23. 제22항에 있어서, T 보조자 펩티드가, a가 D-알라닌이고, X가 사이클로헥실알라닌인 일반식 aKXVAAWTLKAAa를 갖는 약할 조성물
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703753A 1993-03-05 1994-03-04 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) KR960700739A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2714693A 1993-03-05 1993-03-05
US08/027,146 1993-03-05
US7320593A 1993-06-04 1993-06-04
US08/073,205 1993-06-04
US15918493A 1993-11-29 1993-11-29
US08/159,184 1993-11-29
PCT/US1994/002353 WO1994020127A1 (en) 1993-03-05 1994-03-04 Hla-a2.1 binding peptides and their uses

Publications (1)

Publication Number Publication Date
KR960700739A true KR960700739A (ko) 1996-02-24

Family

ID=27362951

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703753A KR960700739A (ko) 1993-03-05 1994-03-04 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)

Country Status (12)

Country Link
EP (1) EP0703783B1 (ko)
JP (1) JP3908271B2 (ko)
KR (1) KR960700739A (ko)
CN (1) CN1118572A (ko)
AT (1) ATE466869T1 (ko)
AU (2) AU6359494A (ko)
BR (1) BR9406652A (ko)
CA (1) CA2157510A1 (ko)
DE (1) DE69435292D1 (ko)
NZ (1) NZ263050A (ko)
SG (1) SG49008A1 (ko)
WO (1) WO1994020127A1 (ko)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
WO1994019011A1 (en) * 1993-02-26 1994-09-01 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0726758B1 (en) * 1993-08-02 2002-11-06 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
EP0728764A4 (en) * 1993-10-19 1999-01-20 Ajinomoto Kk PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
EP0754193B1 (en) * 1994-04-08 2000-06-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
US5935797A (en) * 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
DE69617396T2 (de) * 1995-01-16 2002-09-05 North Sydney Area Health Serv T-Zellen beeinflussende Peptide
GB9501300D0 (en) * 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
SE9501067D0 (sv) 1995-03-24 1995-03-24 Astra Ab New peptides
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US5858972A (en) * 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
AU1582797A (en) * 1996-01-24 1997-08-20 Epimmune, Inc. Induction of immune response against desired determinants
US5723579A (en) * 1996-02-02 1998-03-03 Bayer Corporation Fibrinogen binding peptides
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
CA2248667C (en) * 1996-03-21 2012-06-05 Epimmune Inc. Hla-a2.1 binding peptides and their uses
EP1767542B1 (en) * 1996-03-21 2016-05-11 Epimmune Inc. HLA-A2.1 binding peptides and their uses
US7192928B1 (en) 1996-06-11 2007-03-20 Northern Sydney & Central Coast Area Health Services T cell antigen receptor peptides
US6465251B1 (en) 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
ATE467690T1 (de) * 1997-08-01 2010-05-15 Bio Rad Laboratories Synthetisches antigen zum nachweis von hiv- immunreaktiven antikörpern
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
CN1286696A (zh) * 1998-01-19 2001-03-07 牧岩生命工学研究所 含有来自乙肝病毒x蛋白的肽抗原的脂质体
WO1999040930A1 (en) 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
EP0955311A3 (en) * 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
AU4577899A (en) * 1998-06-17 2000-01-05 Epimmune, Inc. Hla binding peptides and their uses
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2341642C (en) * 1998-09-01 2011-05-24 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
CA2329152A1 (en) * 1999-03-30 2000-10-05 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
EP1082346A1 (en) * 1999-03-30 2001-03-14 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP1176986B1 (en) 1999-04-20 2018-07-04 Yale University Differentiation of monocytes into functional dendritic cells
CA2370413A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US7129052B1 (en) 2000-07-12 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
DE60043158D1 (de) 1999-11-18 2009-11-26 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
ATE298346T1 (de) * 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1242049A4 (en) * 1999-12-13 2005-01-05 Epimmune Inc HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINES
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
WO2001074859A2 (en) 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
NZ522807A (en) * 2000-05-12 2004-11-26 Northwest Biotherapeutics Inc Method to increase class I presentation of exogenous antigens by human dendritic cells
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2002020616A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7189513B2 (en) 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20050032742A1 (en) 2001-08-17 2005-02-10 Defrees Shawn Chemo-enzymatic synthesis of sialylated oligosaccharides
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
MXPA05002455A (es) * 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
EP1903056A3 (en) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2516080C (en) 2003-02-14 2021-11-02 Provid Pharmaceuticals, Inc. Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
JP4676426B2 (ja) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト 改良型ワクチン
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
AU2004232971A1 (en) 2003-04-18 2004-11-04 Idm Pharma Inc. HLA-A2 tumor associated antigen peptides and compositions
ATE541052T1 (de) 2003-05-30 2012-01-15 Agensys Inc Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon
JP4734241B2 (ja) 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
CN102659922B (zh) * 2003-09-22 2013-11-06 株式会社绿多肽 来源于c型肝炎病毒的肽
US7348007B2 (en) * 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
EP1757687A4 (en) * 2004-04-30 2008-01-16 Nec Corp HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
KR100790646B1 (ko) * 2004-07-03 2008-01-02 재단법인 목암생명공학연구소 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
FR2887884B1 (fr) * 2005-06-29 2007-09-14 Pasteur Institut Epitopes de la proteine hbsp et leurs applications biotechnologiques et medicales, notamment pour le traitement de l'hepatite b chronique
CA2622036A1 (en) * 2005-09-08 2007-03-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, In C. Targeted identification of immunogenic peptides
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
US20090023895A1 (en) * 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
US8324345B2 (en) 2006-10-12 2012-12-04 Nec Corporation HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
DE102007059924A1 (de) 2007-12-03 2009-06-04 Eberhard-Karls-Universität Tübingen Universitätsklinikum Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide
US8367801B2 (en) * 2008-01-10 2013-02-05 Endocrine Pharmaceuticals Limited Proteinaceous compounds
US9249187B2 (en) * 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
WO2011064779A2 (en) * 2009-11-29 2011-06-03 Yeda Research And Development Co. Ltd. PEPTIDES DERIVED FROM HIV-1 gp41 TRANSMEMBRANE DOMAIN AND METHODS OF USE THEREOF
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CN111093691A (zh) 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
US20210380644A1 (en) * 2018-10-26 2021-12-09 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
CU20230011A7 (es) 2020-08-13 2023-12-07 Biontech Us Inc Composiciones y métodos de fabricación de células t
AU2021325082A1 (en) 2020-08-13 2023-04-20 Biontech Us Inc. RAS neoantigens and uses thereof
WO2022132596A2 (en) 2020-12-14 2022-06-23 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
CA3232870A1 (en) 2021-09-22 2023-03-30 Richard B. Gaynor Coronavirus vaccines and methods of use
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0643726B1 (en) * 1992-05-26 1999-08-18 Rijksuniversiteit te Leiden PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
EP0703783A4 (en) 1999-03-10
EP0703783B1 (en) 2010-05-05
WO1994020127A1 (en) 1994-09-15
JP3908271B2 (ja) 2007-04-25
DE69435292D1 (de) 2010-06-17
EP0703783A1 (en) 1996-04-03
BR9406652A (pt) 1996-09-10
ATE466869T1 (de) 2010-05-15
CN1118572A (zh) 1996-03-13
WO1994020127A9 (en) 2003-04-17
AU6359494A (en) 1994-09-26
AU6597998A (en) 1998-07-02
JPH08507525A (ja) 1996-08-13
SG49008A1 (en) 1998-05-18
CA2157510A1 (en) 1994-09-15
NZ263050A (en) 1997-11-24

Similar Documents

Publication Publication Date Title
KR960700739A (ko) Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
DeLange et al. Histone III: III. SEQUENCE STUDIES ON THE CYANOGEN BROMIDE PEPTIDES; COMPLETE AMINO ACID SEQUENCE OF CALF THYMUS HISTONE III
Nicholas et al. Synthesis and invitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor
KR960703942A (ko) 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG)
KR840002900A (ko) 생리활성 펩티드를 산출하는 변이물의 제조방법
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
CA2440303A1 (en) Wt1 modified peptide
US4003884A (en) Peptides having LH-RH/FSH-RH activity
AU716716B2 (en) Cysteine protease inhibitors for use in treatment of IgE mediated allergic diseases
ATE113063T1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
KR900009694A (ko) 급속히 분해가능한, hiv 프로테아제용 기질
KR840009069A (ko) 향정신성 펩티드류의 제조 방법
CA2320429A1 (en) Antimicrobial peptides and derived metapeptides
AU650236B2 (en) Substitution analogues of magainin peptides
ATE121754T1 (de) Vakzine gegen bordetella.
ATE282634T1 (de) Chaperonin 10
Kress et al. The Basic Trypsin Inhibitor of Bovine Pancreas: IX. LOCATION OF THE REACTIVE SITE IN THE CARBOXAMIDOMETHYL DERIVATIVE
ATE242202T1 (de) Peptide
Strong et al. Amino acid sequence studies on the. alpha. chain of human fibrinogen. Complete sequence of the largest cyanogen bromide fragment
ATE395361T1 (de) Das h-y antigen
Nair et al. STRUCTURAL CHARACTERISTICS OF PROLYL RESIDUES—A REVIEW.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application